Sign in

    Rohan Mata

    Senior Analyst at Oppenheimer & Co. Inc.

    Rohan Mathur is a Senior Analyst at Oppenheimer & Co. Inc., specializing in biotechnology and pharmaceutical sector research. He is recognized for his coverage of notable companies in the biotech space, contributing in-depth analysis and recommendations that have informed investor decisions, although specific performance metrics or rankings such as TipRanks success rates are not publicly available. Mathur joined Oppenheimer as an analyst focused on the life sciences sector; details about his previous experience or a precise career start date are not readily accessible. He holds FINRA registration as a broker with Oppenheimer & Co. Inc. and maintains the relevant securities licenses required for his role.

    Rohan Mata's questions to Crinetics Pharmaceuticals (CRNX) leadership

    Rohan Mata's questions to Crinetics Pharmaceuticals (CRNX) leadership • Q2 2025

    Question

    An analyst on behalf of Rohan Mata from Oppenheimer & Co. Inc. asked how Crinetics plans to manage the progression toward NDA submission and labeling discussions for adamelin, given the different timelines for the adult and pediatric CAH trials.

    Answer

    Chief Medical & Development Officer Dana Pizzuti stated that the company views the adult and pediatric programs as distinct submissions. She explained that they will not hold one for the other; the adult Phase III trial is expected to finish first and will be submitted. Following a successful outcome, the company would then submit a supplement or amendment to add the pediatric data and indication.

    Ask Fintool Equity Research AI